@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix go: . @prefix hasAgent: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:3238; a Protein: . sub:_2 hasAgent: sub:_3; a go:0042789 . sub:_3 geneProductOf: hgnc:11205; a Protein: . sub:_4 occursIn: species:9606; rdf:object sub:_2; rdf:predicate belv:decreases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:EGR1) -| tscript(p(HGNC:SP1))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_6; pav:version "20131211" . sub:_5 prov:value "Although the evidence implicating Egr-1 in IMPDH type II expression is circumstantial at present, the presence of a protected region (C) corresponding to the Egr-1 binding site in the IMPDH type II promoter and the requirement for increased IMPDH gene expression for T lymphocyte activation do suggest that this site could be of considerable functional importance. It has been observed, for example, that Egr-1 can act as a repressor of Sp1 activity at the coincident binding site in the adenosine deaminase gene promoter"; prov:wasQuotedFrom pubmed:7896827 . sub:_6 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:7896827; prov:wasDerivedFrom beldoc:, sub:_5 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:47.081+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }